Drug safety evaluation of defibrotide

Bibliography

• Kornblum N, Ayyanar K, Benimetskaya L, Defibrotide, a polydisperse mixture of single-stranded phosphodiester oligonucleotides with lifesaving activity in severe hepatic veno-occlusive disease: clinical outcomes and potential mechanisms of action. Oligonucleotides 2006;16:105-14
   PubMed Web of Science ®Google Scholar
• Palmer KJ, Goa KL. Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. Drugs 1993;45:259-94
   PubMed Web of Science ®Google Scholar
• Coccheri S, De Rosa V, Dettori AG, Effect on fibrinolysis of a new antithrombotic agent: fraction P (Defibrotide). A multicentre trial. Int J Clin Pharmacol Res 1982;2:227-45
   Google Scholar
• Coccheri S, Biagi G. Defibrotide. Cardiovasc Drug Rev 1991;9:172-96
   Web of Science ®Google Scholar
• Falanga A, Vignoli A, Marchetti M, Barbui T. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia 2003;17:1636-42
   PubMed Web of Science ®Google Scholar
• Palomo M, Diaz-Ricart M, Rovira M, Defibrotide prevents the activation of macrovascular and microvascular endothelia caused by soluble factors released to blood by autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011;17:497-506
   PubMed Web of Science ®Google Scholar
• Guglielmelli T, Bringhen S, Palumbo A. Update on the use of defibrotide. Expert Opin Biol Ther 2012;12:353-61
   PubMed Web of Science ®Google Scholar
• Public summary of positive opinion for orphan designation of defibrotide for the treatment of hepatic veno-occlusive disease (VOD). EMA. 2005. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2009/10/WC500006113.pdf [Last accessed 22 August 2012]
   Google Scholar
• Public summary of positive opinion for orphan designation of defibrotide for the treatment of hepatic veno-occlusive disease (VOD). EMA. 2005. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2009/10/WC500006112.pdf [Last accessed 22 August 2012]
   Google Scholar
• FDA orphan drug designation. Available from: http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm [Last accessed 22 August 2012]
   Google Scholar
• Bilsel S, Erşahin C, Taga Y, Emerk K. Subcellular localization of radioactively labelled defibrotide in cultured endothelial cells. Thromb Res 1992;66:385-90
   PubMed Web of Science ®Google Scholar
• Bianchi G, Barone D, Lanzarotti E, Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist. Eur J Pharmacol 1993;238:327-34
   PubMed Web of Science ®Google Scholar
• Morabito F, Gentile M, Gay F, Insights into defibrotide: an updated review. Expert Opin Biol Ther 2009;9:763-72
   PubMed Web of Science ®Google Scholar
• Pellegatta F, Lu Y, Radaelli A, Drug-induced in vitro inhibition of neutrophil-endothelial cell adhesion. Br J Pharmacol 1996;118:471-6
   PubMed Web of Science ®Google Scholar
• Benimetskaya L, Wu S, Voskresenskiy AM, Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. Blood 2008;112:4343-52
   PubMed Web of Science ®Google Scholar
• Schröder H. Defibrotide protects endothelial cells, but not L929 tumour cells, from tumour necrosis factor-alpha-mediated cytotoxicity. J Pharm Pharmacol 1995;47:250-2
   PubMed Web of Science ®Google Scholar
• Eissner G, Multhoff G, Gerbitz A, Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. Blood 2002;100:334-40
   PubMed Web of Science ®Google Scholar
• Echart C, Eissner G, Holler E, Iacobelli M. Defibrotide protects human microvascular endothelial cells from fludarabine-mediated pro-inflammatory and pro-apoptotic signals: a microarray (Affimetrix) analysis. Bone Marrow Transplant 2010;45(Suppl 2):S281
   Google Scholar
• Ostrovsky O, Shimoni A, Rand A, Genetic variations in the heparanase gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell transplantation: effect of discrepancy between recipients and donors. Blood 2010;115:2319-28
   PubMed Web of Science ®Google Scholar
• Zhou Q, Chu X, Ruan C. Defibrotide stimulates expression of thrombomodulin in human endothelial cells. Thromb Haemost 1994;71:507-10
   PubMed Web of Science ®Google Scholar
• Cella G, Sbarai A, Mazzaro G, Tissue factor pathway inhibitor release induced by defibrotide and heparins. Clin Appl Thromb Hemost 2001;7:225-8
   PubMed Web of Science ®Google Scholar
• Biagi G, Legnani C, Rodorigo G, Coccheri S. Modulation of arachidonate metabolite generation in human blood by oral defibrotide. Arzneimittelforschung 1991;41:511-14
   PubMed Web of Science ®Google Scholar
• Coccheri S, Biagi G, Legnani C, Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man. Eur J Clin Pharmacol 1988;35:151-6
   PubMed Web of Science ®Google Scholar
• Belcaro G, Legnini M, Cianchetti E, Clinical evaluation of defibrotide in the treatment of arterial and venous vascular disease. A preliminary report. Panminerva Med 1989;31:34-41
   PubMed Web of Science ®Google Scholar
• Craveri A, Tornaghi G, Ranieri R, Effects of defibrotide after oral and parenteral administration in patients with peripheral obliterative arterial disease (POAD). Int Angiol 1990;9:274-7
   PubMed Web of Science ®Google Scholar
• Sabbá C, Zupo V, Dina F, A pilot evaluation of the effect of defibrotide in patients affected by peripheral arterial occlusive disease. Int J Clin Pharmacol Ther Toxicol 1988;26:249-52
   PubMedGoogle Scholar
• Strano A, Fareed J, Sabbá C, A double-blind, multicenter, placebo-controlled, dose comparison study of orally administered defibrotide: preliminary results in patients with peripheral arterial disease. Semin Thromb Hemost 1991;17(Suppl 2):228-34
   PubMedGoogle Scholar
• Ciavarella N, Ettorre C, Schiavoni M, Effectiveness of defibrotide for prophylaxis of deep venous thrombosis in gynecological surgery: a double-blind, placebo-controlled clinical trial. Haemostasis 1986;16(Suppl 1):39-41
   PubMedGoogle Scholar
• Ferrari A, Dindelli M, Sellaroli CM. Preventing postoperative deep venous thrombosis in gynecological surgery with defibrotide. Int Surg 1990;75:184-8
   PubMed Web of Science ®Google Scholar
• Mozzi E, Chiurazzi D, Germiniani R, Pacini F. Effectiveness of defibrotide for prophylaxis of deep venous thrombosis after general surgery: a double-blind, placebo-controlled clinical trial. Haemostasis 1986;16(Suppl 1):36-8
   PubMedGoogle Scholar
• Zanasi R, Fioretta G, Ciocia G, Bergonzi M. Prevention of deep venous thrombosis in orthopedic surgery: effects of defibrotide. Clin Ther 1988;10:350-7
   PubMed Web of Science ®Google Scholar
• Palareti G, Guazzaloca G, Legnani C, Prophylaxis of venous thrombosis after gynaecological surgery: a controlled pilot study of defibrotide. Haematologica 1992;77:44-8
   PubMedGoogle Scholar
• Carreras E, Díaz-Beyá M, Rosiñol L, The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transplant 2011;17:1713-20
   PubMed Web of Science ®Google Scholar
• Coppell JA, Richardson PG, Soiffer R, Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant 2010;16:157-68
   PubMed Web of Science ®Google Scholar
• Corbacioglu S, Hönig M, Lahr G, Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide. Bone Marrow Transplant 2006;38:547-53
   PubMed Web of Science ®Google Scholar
• Corbacioglu S, Cesaro S, Faraci M, Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet 2012;379:1301-9
   PubMed Web of Science ®Google Scholar
• Cesaro S, Spiller M, Sartori MT, Veno-occlusive disease in pediatric patients affected by Wilms tumor. Pediatr Blood Cancer 2011;57:258-61
   PubMed Web of Science ®Google Scholar
• Chalandon Y, Roosnek E, Mermillod B, Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2004;10:347-54
   PubMed Web of Science ®Google Scholar
• Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995;85:3005-20
   PubMed Web of Science ®Google Scholar
• Carreras E. Early complications after HSCT. In: Apperley J, Carreras E, Gluckman E, Masszi T, editors. ESH-EBMT handbook on haematopoietic stem cell transplantation. Forum Service Editore; Genova: 2012. p. 176-95
   Google Scholar
• Coppell JA, Brown SA, Perry DJ. Veno-occlusive disease: cytokines, genetics, and haemostasis. Blood Rev 2003;17:63-70
   PubMed Web of Science ®Google Scholar
• Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000;275:2247-50
   PubMed Web of Science ®Google Scholar
• DeLeve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology 2009;49:1729-64
   PubMed Web of Science ®Google Scholar
• Richardson PG, Soiffer RJ, Antin JH, Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant 2010;16:1005-17
   PubMed Web of Science ®Google Scholar
• Coccheri S, Andreozzi GM, D'Addato M, Gensini GF. Effects of defibrotide in patients with chronic deep insufficiency. The PROVEDIS study. Int Angiol 2004;23:100-7
   PubMed Web of Science ®Google Scholar
• Artesani MC. Anaphylactic shock to defibrotide. Allergy 2006;61:1022
   PubMed Web of Science ®Google Scholar
• Ulutin ON, Ilhan-Berkel N, Tunali H, Effects of defibrotide on peripheral obliterative vascular diseases. Haemostasis 1986;16(Suppl 1):59-62
   PubMedGoogle Scholar
• Violi F, Ferro D, Saliola M, Effect of oral defibrotide on tissue-plasminogen activator and tissue-plasminogen activator inhibitor balance. Eur J Clin Pharmacol 1992;42:379-83
   PubMed Web of Science ®Google Scholar
• Di Perri T, Vittoria A, Messa GL, Cappelli R. Defibrotide therapy for thrombophlebitis-controlled clinical trial. Haemostasis 1986;16(Suppl 1):42-7
   PubMedGoogle Scholar
• Belcaro G, Marelli C, Pomante P, Fibrinolytic enhancement in diabetic microangiopathy with defibrotide. Angiology 1992;43:793-800
   PubMed Web of Science ®Google Scholar
• Tubaro M, Mattioli G, Matta F, Defibrotide versus heparin in the prevention of coronary reocclusion after thrombolysis in acute myocardial infarction. Cardiovasc Drugs Ther 1993;7:809-16
   PubMed Web of Science ®Google Scholar
• Carelli M, Citone C, Di Marcotullio G, A pilot evaluation of the effects of defibrotide in patients affected by acute myocardial infarction. Semin Thromb Hemost 1988;14(Suppl):71-6
   PubMedGoogle Scholar
• Palumbo A, Larocca A, Genuardi M, Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. Haematologica 2010;95:1144-9
   PubMed Web of Science ®Google Scholar
• Francischetti IM, Oliveira CJ, Ostera GR, Defibrotide interferes with several steps of the coagulation-inflammation cycle and exhibits therapeutic potential to treat severe malaria. Arterioscler Thromb Vasc Biol 2012;32:786-98
   PubMed Web of Science ®Google Scholar
• Richardson PG, Murakami C, Jin Z, Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002;100:4337-43
   PubMed Web of Science ®Google Scholar
• Zwaan CM, Reinhardt D, Zimmerman M, Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. Br J Haematol 2010;148:768-76
   PubMed Web of Science ®Google Scholar
• Cohen JM, Akl EA, Kahn SR. Pharmacologic and compression therapies for postthrombotic syndrome: a systematic review of randomized controlled trials. Chest 2012;141:308-20
   PubMed Web of Science ®Google Scholar
• Fareed J, Walenga JM, Cornelli U. Antithrombotic drugs in pelvic surgery. Semin Thromb Hemost 1989;15:230-2
   PubMed Web of Science ®Google Scholar
• Pegram AA, Kennedy LD. Prevention and treatment of veno-occlusive disease. Ann Pharmacother 2001;35:935-42
   PubMed Web of Science ®Google Scholar
• Corbacioglu S, Carreras E, Niederwieser DW, Safety of defibrotide (DF) in stem cell transplant (SCT) patients (Pts). Blood (ASH annual meeting abstract) 2010;116:abstract 3482
   Google Scholar
• Chopra R, Eaton JD, Grassi A, Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 2000;111:1122-9
   PubMed Web of Science ®Google Scholar
• Richardson PG, Elias AD, Krishnan A, Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 1998;92:737-44
   PubMed Web of Science ®Google Scholar
• Ramasamy K, Lim ZY, Pagliuca A, Incidence and management of hepatic venoocclusive disease in 237 patients undergoing reduced-intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant 2006;38:823-4
   PubMed Web of Science ®Google Scholar
• Sucak GT, Aki ZS, Yagcí M, Treatment of sinusoidal obstruction syndrome with defibrotide: a single-center experience. Transplant Proc 2007;39:1558-63
   PubMed Web of Science ®Google Scholar
• Richardson PG, Tomblyn M, Kernan N, Defibrotide (DF) in the treatment of severe hepatic veno-occlusive disease (VOD) with multi-organ failure (MOF) following stem cell transplantation (SCT): results of a phase 3 study utilizing a historical control. Blood (ASH annual meeting abstract) 2009;114:abstract 654
   Google Scholar
• Horn B, Reiss U, Matthay K, Veno-occlusive disease of the liver in children with solid tumors undergoing autologous hematopoietic progenitor cell transplantation: a high incidence in patients with neuroblastoma. Bone Marrow Transplant 2002;29:409-15
   PubMed Web of Science ®Google Scholar
• Richardson PG, Smith AR, Grupp SA, Defibrotide (DF) in the treatment of hepatic veno-occlusive disease (VOD) in stem cell transplant (SCT) and non-SCT patients (Pts): early intervention improves outcome – Updated results of a treatment IND expanded access protocol. Blood (ASH annual meeting abstract) 2011;118:abstract 487
   Google Scholar
• Barker CC, Butzner JD, Anderson RA, Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2003;32:79-87
   PubMed Web of Science ®Google Scholar
• Cesaro S, Pillon M, Talenti E, A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Haematologica 2005;90:1396-404
   PubMed Web of Science ®Google Scholar
• Reiss U, Cowan M, McMillan A, Horn B. Hepatic venoocclusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients. J Pediatr Hematol Oncol 2002;24:746-50
   PubMed Web of Science ®Google Scholar
• Haussmann U, Fischer J, Eber S, Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy. Haematologica 2006;91:795-800
   PubMed Web of Science ®Google Scholar
• Cappelli B, Chiesa R, Evangelio C, Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous Busulphan. Br J Haematol 2009;147:554-60
   PubMed Web of Science ®Google Scholar
• Mare M, Maisano R, Caristi N, Venous damage prevention by defibrotide in vinorelbine-treated patients. Support Care Cancer 2003;11:593-6
   PubMed Web of Science ®Google Scholar
• Maisano R, Adamo V, Toscano G, Defibrotide in the prevention of venous irritation by vinorelbine administration. Anticancer Res 1997;17:2775-7
   PubMed Web of Science ®Google Scholar
• Perotti C, Torretta L, Costamagna L, Salvaneschi L. Thrombotic thrombocytopenic purpura after defibrotide therapy. Haematologica 1994;79:569
   PubMedGoogle Scholar
• Corti P, Uderzo C, Tagliabue A, Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation. Bone Marrow Transplant 2002;29:542-3
   PubMed Web of Science ®Google Scholar
• Pogliani EM, Perseghin P, Parma M, Defibrotide in recurrent thrombotic thrombocytopenic purpura. Clin Appl Thromb Hemost 2000;6:69-70
   PubMed Web of Science ®Google Scholar
• Bonomini V, Vangelista A, Frascà G. A new antithrombotic agent in the treatment of acute renal failure due to hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura. Nephron 1984;37:144
   PubMed Web of Science ®Google Scholar
• Belcaro G. Evolution of superficial vein thrombosis treated with defibrotide: comparison with low dose subcutaneous heparin. Int J Tissue React 1990;12:319-24
   PubMedGoogle Scholar
• Bonomini V, Frascà GM, Raimondi C, Effect of a new antithrombotic agent (defibrotide) in acute renal failure due to thrombotic microangiopathy. Nephron 1985;40:195-200
   PubMed Web of Science ®Google Scholar
• Mattioli G, Cappello C, Fusaro MT. Treatment of acute myocardial infarction with defibrotide. Semin Thromb Hemost 1989;15:470-3
   PubMed Web of Science ®Google Scholar
• Milazzotto F, Carelli M, Citone C, Use of defibrotide in the treatment of acute myocardial infarction. Semin Thromb Hemost 1989;15:464-9
   PubMed Web of Science ®Google Scholar
• Vangelista A, Frascà GM, Raimondi C, Effects of defibrotide in acute renal failure due to thrombotic microangiopathy. Haemostasis 1986;16(Suppl 1):51-4
   PubMedGoogle Scholar
• Palumbo A, Bringhen S, Caravita T, Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367:825-31
   PubMed Web of Science ®Google Scholar
• Vingolo EM, De Mattia G, Giusti C, Treatment of nonproliferative diabetic retinopathy with Defibrotide in noninsulin-dependent diabetes mellitus: a pilot study. Acta Ophthalmol Scand 1999;77:315-20
   PubMedGoogle Scholar
• Bonomini V, Vangelista A, Stefoni S, Use of defibrotide in renal transplantation in man. Haemostasis 1986;16(suppl 1):48-50
   PubMedGoogle Scholar
• Filimberti E, Cinotti S, Salvadori M, Hemodialysis with defibrotide: effects on coagulation parameters. Int J Artif Organs 1992;15:590-4
   PubMed Web of Science ®Google Scholar
• Frascà GM, Martello M, Sestigiani E, Effects of defibrotide treatment in patients with IgA nephropathy and reduced renal function. Nephrol Dial Transplant 1996;11:392-3
   PubMed Web of Science ®Google Scholar
• Cimminiello C, Milani M, Pietra A, Deficient fibrinolytic response in patients with Raynaud's phenomenon and its correction with defibrotide. Semin Thromb Hemost 1991;17(Suppl 1):106-11
   PubMedGoogle Scholar
• Corbacioglu S, Greil J, Peters C, Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant 2004;33:189-95
   PubMed Web of Science ®Google Scholar
• Bulley SR, Strahm B, Doyle J, Dupuis LL. Defibrotide for the treatment of hepatic veno-occlusive disease in children. Pediatr Blood Cancer 2007;48:700-4
   PubMed Web of Science ®Google Scholar
• Dignan F, Gujral D, Ethell M, Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease. Bone Marrow Transplant 2007;40:79-82
   PubMed Web of Science ®Google Scholar
• Bonini A, Imovilli A, Ghirarduzzi A, Defibrotide low-dose continuous infusion after allogenic stem cell transplantation as prophylaxis for veno-occlusive disease of the liver. Blood (ASH annual meeting abstract) 2010;116:abstract 3483
   Google Scholar
• Park M, Park HJ, Eom H-S, Effects of prophylactic defibrotide for veno-occlusive disease in haematopoietic stem cell transplantation. Blood (ASH annual meeting abstract) 2011;118:abstract 4517
   Google Scholar
• Versluys B, Bhattacharaya R, Steward C, Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure. Blood 2004;103:1968
   PubMed Web of Science ®Google Scholar